XORTX Therapeutics Inc.
XRTX • Biotechnology
$0.96
▼ -0.05 (-5.40%)
Current price
EarningsLatest report: Jun 30, 2026
HIGHER-RISK PROFILECautionConfidence: 70%
Quantitative profile — not an investment recommendation.
Quantitative profile — not an investment recommendation.Methodology
Analysis thesis: Caution is warranted. Recent ratios show weaknesses that may limit returns unless fundamentals improve.
Market Cap
$1.55M
Growth
—
Cash Flow
0/5
Trend
Negative
Evidence
Manageable debt level · 0.02Healthy liquidity · 1.61Weak profitability
Financial data as of: Jun 30, 2026, 12:00 AM UTCLast earnings update: Jun 30, 2026, 12:00 AM UTCLast profile update: Aug 19, 2026, 12:24 PM UTC
Company Snapshot
Key valuation, quality, financial strength, momentum and analyst data.
Price$0.96
Change-5.40%
Shares Out1.62M
Market Cap$1.55M
Enterprise Value$552.87K
52W Range1.73 - 7.05
Beta0.08
P/E-0.42
P/B0.28
P/FCF-0.30
EV/EBITDA-0.15
EV/FCF-0.11
Price$0.96
Change-5.40%
Shares Out1.62M
Market Cap$1.55M
Enterprise Value$552.87K
52W Range1.73 - 7.05
Beta0.08
P/E-0.42
P/B0.28
P/FCF-0.30
EV/EBITDA-0.15
EV/FCF-0.11
Earnings Yield-239.13%
FCF Yield-334.70%
Dividend Yield0.00%
Gross Margin0.00%
Oper. Margin0.00%
Profit Margin0.00%
Debt/Eq0.02
Current Ratio1.61
Quick Ratio1.61
Volume7.59K
Avg Volume22.80K
EPS Surprise0.39
Investment DNA
How strong this company looks for long-term investors
47
out of 100
Business Quality
Margins, moat, returns
22/100
Financial Strength
Debt, cash, stability
73/100
Growth Potential
Revenue and expansion
50/100
Price Attractiveness
Cheap or expensive today
95/100
Why this score▼
Manageable debt level · 0.02Healthy liquidity · 1.61Weak profitability
Analyst view
No analyst data available now.
🧾
No insider activity
No recent insider transactions available.